By Hannah McLane, Courtney Hutchison, Daniel Wikler, Timothy Howell, & Emma Knighton. Research into psychedelic-assisted therapy has grown in the past ten years as non-profits, academic institutions, pharmaceutical companies, and even venture capitalists race to develop protocols for using MDMA, psilocybin, ketamine, and other psychedelic substances to treat mental illness. Already, dozens of ketamine clinics […]
Category: Drug policy
FDA approves aducanumab – do not get carried away!
By Erik Gustavsson, Pauline Raaschou, Gerd Lärfars, Lars Sandman, Niklas Juth. In spring 2019 Gerd Lärfars (head of the pharmaceutical division at the Stockholm Region in Sweden) suggested that we put together an interdisciplinary group consisting of clinicians, medical ethicists, and scholars with experience in health care administration. The aim for this group would be […]
Removing the legal barriers to treating the excruciating pain of cluster headaches
By Jonathan Leighton. There is nothing worse than extreme pain and suffering. Patients experiencing unbearable pain may take their lives to escape it. The highest priority of medicine and of society in general – the issue with the most urgent call to action – is arguably to alleviate such suffering. Although the ethical framework I […]